# Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)

> **NCT00508001** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 67 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Vandetanib
- **DRUG:** Vandetanib
- **DRUG:** Best Supportive Care

## Key facts

- **NCT ID:** NCT00508001
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-11
- **Final completion:** 2009-06
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2016-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00508001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00508001, "Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00508001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*